EMEA-001178-PIP01-11-M03

Key facts

Invented name
Stivarga
Active substance
regorafenib
Therapeutic area
Oncology
Decision number
P/0091/2017
PIP number
EMEA-001178-PIP01-11-M03
Pharmaceutical form(s)
  • Film-coated tablet
  • granules
Condition(s) / indication(s)
Treatment of all conditions contained in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)
Route(s) of administration
Oral use
Contact for public enquiries
Bayer Pharma AG
Germany
E-mail: pediatrics.medical-affairs-europe@bayer.com
Tel. +49 3046815333
Fax +49 3046895333
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating